摘要
为观察尿激酶天普洛欣(UKTP)经静脉溶栓治疗急性心肌梗塞(AMI)的临床有效性及安全性。收集协作组148家医院1994年11月至1996年4月经静脉UKTP溶栓治疗AMI患者1406例,观察临床疗效、副作用及病死率等。其中124例行90分钟冠状动脉造影评价梗塞血管开通情况。结果:梗塞血管临床再灌注率为73.5%,90分钟冠状动脉造影血管开通率为72.6%,5周总病死率为7.8%(109/1406),轻度出血10.2%(143/1406),中重度出血0.43%(6/1406),脑出血0.50%(7/1406)。老年(>65岁)甚至高龄(>75岁)患者溶栓及距发病超过6小时者,其用药仍然安全有效,UKTP合适的用药剂量可能为150万U左右。结果提示UKTP治疗AMI安全有效。
The aims of the study were to observe the clinical efficacy and safety of intravenous thrombolytic therapy using Urokinase Tech Pool (UKTP) in acute myocardial infarcton (AMI). The data were collected from 148 hospitals during November 1994 to April 1996. The clinical therapeutic efficacy, side effects and mortality were analyzed in 1406 patients with AMI treated with UKTP, of which 124 cases underwent coronary artery angiography (CAG) at the 90th minute after beginning of thrombolysis to evaluate the patency of the infarct related artery (IRA). The reperfusion rate in IRAs was 73.5% by clinical standards and 72.6% by the 90th minute CAG. The total mortality in the first 5 weeks was 7.8%(109/1406). The rate of minor bleeding was 10.2% (143/1406), major bleeding 0.43% (6/1406) and intracranial hemorrhage 0.50%(7/1406). They were still effective and safe for elderly patients (aged>75 years. as well as >65 years) and delayed UKTP therapy (>6 hours from onset). The appropriate UKTP dosage might be 150 million IU intravenous infusion within 30 minutes. In conclusions: UKTP therapy is a effective, reliable and safe method for AMI.
出处
《中华心血管病杂志》
CAS
CSCD
北大核心
1997年第3期176-179,共4页
Chinese Journal of Cardiology
关键词
心肌梗塞
尿激酶
溶栓疗法
myocardial infarction urokinase thrombolytic therapy